News Celgene to file potential MS blockbuster this year Success with ozanimod would justify $7.2 billion outlay for Receptos.
News Valeant's Siliq approved but suicidal thoughts warning will ... But drug will have boxed warning over suicidal ideation.
News Trump demands cuts to 'astronomical' drug prices - but pharm... Trump calls pharma leaders to White House to discuss cutting taxes, regulations - and drug prices
News Delinia adds to Celgene's immunology ambitions Celgene continues with focus on autoimmune diseases.
News Celgene broadens immunology presence with Anokion deal Biotech specialises in autoimmune disorder drugs.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
